| Name | Title | Contact Details |
|---|
Customized indirect lending solutions for credit unions looking to compete for members loans and increase market share by adding new members.
Mobile WMS from Tasklet Factory optimizes your warehouse and operations by streamlining functionalities like count, pick, shipping, receive, and more. Our scanner solution is widely recognized as user-friendly and quick to implement. On- and offline fu...
Cambridge Mobile Telematics (CMT) pioneered telematics for usage-based and behavior-based programs making roads and drivers safer around the world. Founded in 2010 by two MIT professors, CMTs accomplished team of expert scientists and experienced entrepreneurs developed DriveWell, an advanced mobile-sensing and big data platform delivering an end-to-end smartphone telematics solution. DriveWell provides valuable feedback to users, helping them to improve driving performance and become more aware of unsafe behaviors. DriveWell is the first telematics platform in the industry to provide both traditional vehicle-centric, usage-based-insurance (UBI) and driver-centric, behavior-based insurance (BBI) solutions. Through the DriveWell program, CMTs partners can easily measure mileage, time of day, roadways and risky driving behaviors - giving them a complete picture of every trip and allowing them to segment high-risk vs low-risk customers easily. CMT has a proven track record of changing driver behavior: an average reduction of 35% in phone distraction, 20% in hard braking, and 20% in at-risk speeding all within 30 days of using the program. With DriveWell, users become safer drivers, resulting in fewer crashes and less-costly claims. The average user sustains a 25% reduction in phone usage even after 200 days, and some CMTs insurance partners report as much as 47% reduction in total claims costs, based on studies of more than 100,000 drivers.
Hacker Factor is a Fort Collins, CO-based company in the Software and Internet sector.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.